Edition:
United States

Integra LifeSciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

42.74USD
24 Mar 2017
Change (% chg)

$0.39 (+0.92%)
Prev Close
$42.35
Open
$42.47
Day's High
$43.02
Day's Low
$42.42
Volume
186,610
Avg. Vol
291,039
52-wk High
$45.84
52-wk Low
$32.02

Latest Key Developments (Source: Significant Developments)

Integra LifeSciences Q4 adjusted earnings per share $0.52
Thursday, 23 Feb 2017 07:00am EST 

Integra LifeSciences Holdings Corp : Integra LifeSciences reports fourth quarter and full-year 2016 financial results and updates 2017 full-year guidance . Sees FY 2017 adjusted earnings per share $1.88 to $1.94 . Sees FY 2017 GAAP earnings per share $0.49 to $0.55 . Q4 adjusted earnings per share $0.52 . Q4 GAAP earnings per share $0.35 . Q4 revenue $255.7 million versus I/B/E/S view $257.3 million . Sees FY 2017 revenue $1.12 billion to $1.14 billion . Q4 earnings per share view $0.52 -- Thomson Reuters I/B/E/S .Fy2017 earnings per share view $1.93, revenue view $1.10 billion -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences to buy Derma Sciences
Tuesday, 10 Jan 2017 08:00pm EST 

Derma Sciences Inc : Derma Sciences to be acquired by Integra Lifesciences for $7.00 per share of common stock in cash . Says will be acquired by Integra Lifesciences Holdings Corporation for $7.00 per share of common stock in cash . Says deal for a total of approximately $204 million . Says Integra will also assume contingent liabilities related to biod transaction . Says q4 net sales of $26.9 million .Says q4 awc net sales of $20.3 million representing growth of 95.6%.  Full Article

Integra lifesciences sees FY 2017 adj shr $1.91 to $1.97
Tuesday, 10 Jan 2017 08:00pm EST 

Integra Lifesciences Holdings Corp : Integra Lifesciences Holdings - expects Q4 2016 gaap and adjusted diluted EPS to be at or above mid-point of prior guidance range of $0.32 to $0.35 and $0.50 to $0.53 respectively . Integra Lifesciences to acquire Derma Sciences Inc. and announces preliminary fourth quarter and full year 2016 financial results and 2017 outlook . Sees FY 2017 adjusted earnings per share $1.91 to $1.97 . Sees FY 2017 revenue about $1.05 billion to $1.07 billion . Sees Q4 2016 revenue about $256 million . Sees FY 2016 revenue about $992 million . Integra Lifesciences- expects deal to add about $65 million in revenue and to be dilutive to adjusted earnings per share by about three cents during 2017 . "Preliminary 2017 guidance does not include acquisition of Derma Sciences, Inc., which has not closed" . Says expects 7% to 8.5% organic revenue growth in 2017 .Derma Sciences acquisition is expected to turn accretive to adjusted earnings in 2018.  Full Article

Integra Lifesciences Holdings files for potential mixed shelf offering - SEC filing
Friday, 4 Nov 2016 08:17am EDT 

Integra Lifesciences Holdings Corp :Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Integra Lifesciences sees 2016 sales $992 mln-$1.002 bln
Thursday, 28 Jul 2016 06:00am EDT 

Integra Lifesciences Holdings Corp : Raising its FY gaap and adjusted eps guidance by $0.04/share and narrowing guidance range to new range of $1.78 - $1.88 and $3.43 - $3.53, respectively . Integra lifesciences reports second quarter 2016 financial results . Q2 adjusted earnings per share $0.79 . Q2 gaap earnings per share $0.32 . Q2 revenue $249.3 million versus i/b/e/s view $243.2 million . Sees fy 2016 sales $992 million to $1.002 billion . Q2 earnings per share view $0.76 -- Thomson Reuters I/B/E/S . Integra lifesciences holdings corp says q2 gaap gross margin was 64.1% and adjusted gross margin was 69.2% . Integra lifesciences holdings corp says raising organic sales guidance to 9%. For 2016 .FY2016 earnings per share view $3.44, revenue view $994.8 million -- Thomson Reuters I/B/E/S.  Full Article

Integra Lifesciences Holdings Corp raises low end of prior guidance range
Wednesday, 27 Apr 2016 06:01am EDT 

Integra Lifesciences Holdings Corp:Raising low end of FY 2016 revenue guidance to a new range of $985 million to $1.0 billion, up from prior guidance of $975 million to $1.0 billion.Raises Fy 2016 organic revenue growth to about 8% from its previous guidance of about 7%.Adjusts low end of its FY 2016 adjusted earnings per share guidance range to $3.38 - $3.50 from $3.35 - $3.50.Says the company's GAAP EPS guidance is now $1.73 to $1.85.  Full Article

Integra LifeSciences Holdings Corp announces Service Alliance Agreement With PREZIO Health
Thursday, 25 Feb 2016 04:30pm EST 

Integra LifeSciences Holdings Corp:Integra Lifesciences announces service alliance agreement with prezio health.Says prezio health will act as integra's authorized surgical instruments service provider.  Full Article

Integra LifeSciences Receives FDA Approval of Integra Dermal Regeneration Template (IDRT) for Treatment of Chronic Diabetic Foot Ulcers (DFU)
Thursday, 7 Jan 2016 02:02pm EST 

Integra LifeSciences Holdings Corporation:Says United States Food and Drug Administration (FDA) has approved the PMA Supplement for Integra Dermal Regeneration Template (IDRT) for treatment of diabetic foot ulcers (DFU).approval of this new indication is based on results from the FOUNDER (FOot Ulcer New DErmal Replacement) Study, a multi-center, randomized, controlled, parallel group clinical trial conducted under an Investigational Device Exemption (IDE).FOUNDER Study showed that patients treated with IDRT demonstrated a 59% improvement in incidence of complete wound closure compared to standard of care.IDRT, with its newly approved DFU indication, will be marketed under the name Integra Omnigraft Dermal Regeneration Template.  Full Article

Integra LifeSciences Holdings Corp raises low end of prior FY 2015 guidance
Tuesday, 3 Nov 2015 06:00am EST 

Integra LifeSciences Holdings Corp:Expects FY 2015 revenue of $878-$885 million, up from prior guidance of $870-$885 million.Expects FY 2015 adjusted EPS in the range of $3.05-$3.10, up from prior guidance of 3.00-$3.10.  Full Article

Integra LifeSciences Holdings Corp files patent infringement lawsuit against HyperBranch Medical Technology, Inc.
Tuesday, 15 Sep 2015 04:15pm EDT 

Integra LifeSciences Holdings Corp:Says filed a lawsuit in the U.S. District Court for the District of Delaware against HyperBranch Medical Technology, Inc.Lawsuit alleges that HyperBranch's Adherus Autospray Dural Sealant, Adherus Dural Sealant, and Adherus Spinal Sealant infringe patents that Integra licenses from Incept LLC.  Full Article

More From Around the Web

BRIEF-Integra Lifesciences reports acceptance of shares tendered into offer for Derma Sciences

* Integra Lifesciences announces acceptance of shares tendered into offer for Derma Sciences, Inc. Source text for Eikon: Further company coverage: